Stay updated on Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial
Sign up to get notified when there's something new on the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page.

Latest updates to the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe ADEPT-3 study added numerous new locations across the globe, including sites in China, Argentina, and the United States (e.g., 7021, 7023–7028). The total number of study locations now reaches 409.SummaryDifference3%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedNew locations and site details were added (e.g., Site 4215 in Iława, Poland and Site 1246 in Naples, FL) and investigator contacts updated. The total number of reported locations now stands at 397.SummaryDifference0.7%

- Check40 days agoChange DetectedAdded 'Last Update Posted (Estimated)' under Study Record Dates. Removed the government funding lapse notice.SummaryDifference0.1%

- Check47 days agoChange DetectedAdded new locations and site details (including Seoul, South Korea; Greater Poland Voivodeship, Poland; São Paulo, Brazil) and removed several sites, with the total locations now listed as 393.SummaryDifference0.7%

- Check61 days agoChange DetectedNo significant updates to the study details are visible between the screenshots; enrollment figures, locations, eligibility criteria, and outcomes appear unchanged (any differences are visual). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedExpanded the study’s location list and recruitment status details (new cities and institutions; some previous sites removed), resulting in a larger, more current set of locations and statuses.SummaryDifference4%

Stay in the know with updates to Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-Term Safety of KarXT in Alzheimer's Psychosis Clinical Trial page.